PDF下载 ( 302 KB)
Expert consensus of Oncology Committee of Chinese Medical Association in early diagnosis and treatment of pancreatic cancer
-
摘要:
胰腺癌是恶性程度最高的消化道恶性肿瘤之一,其发病率和死亡率在国内外都呈快速上升趋势。因其临床表现隐匿,早期诊断缺乏兼具敏感性和特异性的指标,致使胰腺癌的5年生存率低于8%。胰腺癌的早期诊断是世界性难题,早诊率仅为5%;提高早诊率是改善胰腺癌整体预后的关键;实现胰腺癌早诊早治的关键是明确胰腺癌的高危人群,提高早期诊断技术的敏感性和特异性,规范胰腺癌早期诊断的流程以及早期胰腺癌的治疗等。
Abstract:Pancreatic cancer( PC) remains one of the most challenging malignant tumor in gastrointestinal cancer,and the incidence and mortality rates are significantly increased in the past decades. The 5-years survival rate of PC is less than 8% since its dormant clinical symptoms and lacking of sensibility and specificity markers in early diagnosis. The early diagnosis of pancreatic cancer is a worldwide problem,and the early diagnosis rate is only 5%. Increasing early diagnosis rate is the key to improve the overall prognosis of pancreatic cancer.The key of early diagnosis and treatment of pancreatic cancer is to identify the high-risk population of pancreatic cancer,improve the sensitivity and specificity of early diagnosis technology,standardize the process of early diagnosis of pancreatic cancer,and standardize the treatment of early pancreatic cancer. To this end,this expert consensus is formulated.
-
Key words:
- pancreatic neoplasms /
- early diagnosis /
- early treatment /
- consensus
-
[1] SIEGEL RL,MILLER KD,JEMAL A. Cancer statistics,2018[J]. CA Cancer J Clin,2018,68(1):7-30. [2] ZHENG RS,SUN KX,ZHANG SW,et al. Prevalence of malignant tumors in China,2015[J]. Chin J Oncol,2019,41(1):19-28.(in Chinese)郑荣寿，孙可欣，张思维，等．2015年中国恶性肿瘤流行情况分析[J]．中华肿瘤杂志，2019,41(1):19-28. [3] SIEGEL RL,MILLER KD,JEMAL A. Cancer statistics,2020[J]. CA Cancer J Clin,2020,70(1):7-30. [4] ZENG H,CHEN W,ZHENG R,et al. Changing cancer survival in China during 2003-15:A pooled analysis of 17 population-based cancer registries[J]. Lancet Glob Health,2018,6(5):e555-e567. [5] BRODY JR,WITKIEWICZ AK,YEO CJ. The past,present,and future of biomarkers:A need for molecular beacons for the clinical management of pancreatic cancer[J]. Adv Surg,2011,45:301-321. [6] PORUK KE,GAY DZ,BROWN K,et al. The clinical utility of CA 19-9 in pancreatic adenocarcinoma:Diagnostic and prognostic updates[J]. Curr Mol Med,2013,13(3):340-351. [7] ZHAN HY,HUANG CW,LIN LQ,et al. The clinical value of tumor marker CA19-9 and CA242 in pancreatic cancer[J].Clin J Diffic Complcas,2006,5(3):186-188.(in Chinese)詹海勇，黄聪武，林銮群，等．血清糖链抗原19-9和糖链抗原242诊断胰腺癌的临床价值[J]．疑难病杂志，2006,5(3):186-188. [8] LUO G,LIU C,GUO M,et al. Potential biomarkers in lewis negative patients with pancreatic cancer[J]. Ann Surg,2017,265(4):800-805. [9] TONG X,XIAO D,YAO F,et al. Astragalus membranaceus as a cause of increased CA19-9 and liver and kidney cysts:A case report[J]. J Clin Pharm Ther,2014,39(5):561-563. [10] LI X,GUO X,LI H,et al. Serum carbohydrate antigen 242 expression exerts crucial function in the diagnosis of pancreatic cancer[J]. Tumour Biol,2014,35(6):5281-5286. [11] KAUR S,BAINE MJ,JAIN M,et al. Early diagnosis of pancreatic cancer:Challenges and new developments[J]. Biomark Med,2012,6(5):597-612. [12] GU YL,LAN C,PEI H,et al. Applicative value of serum CA19-9,CEA,CA125 and CA242 in diagnosis and prognosis for patients with pancreatic cancer treated by concurrent chemoradiotherapy[J]. Asian Pac J Cancer Prev,2015,16(15):6569-6573. [13] DIAZ LA Jr,BARDELLI A. Liquid biopsies:Genotyping circulating tumor DNA[J]. J Clin Oncol,2014,32(6):579-586. [14] EARL J,GARCIA-NIETO S,MARTINEZ-AVILA JC,et al.Circulating tumor cells(Ctc)and kras mutant circulating free Dna(cfdna)detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer[J]. BMC Cancer,2015,15:797. [15] LIU H,SUN B,WANG S,et al. Circulating tumor cells as a biomarker in pancreatic ductal adenocarcinoma[J]. Cell Physiol Biochem,2017,42(1):373-382. [16] SAUSEN M,PHALLEN J,ADLEFF V,et al. Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients[J]. Nat Commun,2015,6:7686. [17] COHEN JD,JAVED AA,THOBURN C,et al. Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers[J]. Proc Natl Acad Sci U S A,2017,114(38):10202-10207. [18] GANDOLFI L,TORRESAN F,SOLMI L,et al. The role of ultrasound in biliary and pancreatic diseases[J]. Eur J Ultrasound,2003,16(3):141-159. [19] AHN SS,KIM MJ,CHOI JY,et al. Indicative findings of pancreatic cancer in prediagnostic CT[J]. Eur Radiol,2009,19(10):2448-2455. [20] TREADWELL JR,ZAFAR HM,MITCHELL MD,et al. Imaging tests for the diagnosis and staging of pancreatic adenocarcinoma:A meta-analysis[J]. Pancreas,2016,45(6):789-795. [21] FRANCIS IR. Pancreatic adenocarcinoma:Diagnosis and staging using multidetector-row computed tomography(MDCT)and magnetic resonance imaging(MRI)[J]. Cancer Imaging,2007,7(Special issue A):s160-s165. [22] DAS KK,EARLY D. Pancreatic cancer screening[J]. Curr Treat Options Gastroenterol,2017,15(4):562-575. [23] FATTAHI R,BALCI NC,PERMAN WH,et al. Pancreatic diffusion-weighted imaging(DWI):Comparison between massforming focal pancreatitis(FP),pancreatic cancer(PC),and normal pancreas[J]. J Magn Reson Imaging,2009,29(2):350-356. [24] HIRSCH FW,SATTLER B,SORGE I,et al. PET/MR in children. Initial clinical experience in paediatric oncology using an integrated PET/MR scanner[J]. Pediatr Radiol,2013,43(7):860-875. [25] OZAWA Y,NUMATA K,TANAKA K,et al. Contrast-enhanced sonography of small pancreatic mass lesions[J]. J Ultrasound Med,2002,21(9):983-991. [26] HIROOKA Y,GOTO H,ITO A,et al. Recent advances in US diagnosis of pancreatic cancer[J]. Hepatogastroenterology,2001,48(40):916-922. [27] AGARWAL B,ABU-HAMDA E,MOLKE KL,et al. Endoscopic ultrasound-guided fine needle aspiration and multidetector spiral CT in the diagnosis of pancreatic cancer[J]. Am J Gastroenterol,2004,99(5):844-850. [28] BUCHS NC,FROSSARD JL,ROSSET A,et al. Vascular invasion in pancreatic cancer:Evaluation of endoscopic ultrasonography, computed tomography, ultrasonography, and angiography[J]. Swiss Med Wkly,2007,137(19-20):286-291. [29] FUSAROLI P,SPADA A,MANCINO MG,et al. Contrast harmonic echo-endoscopic ultrasound improves accuracy in diagnosis of solid pancreatic masses[J]. Clin Gastroenterol Hepatol,2010,8(7):629-634. [30] OHNO E,ITOH A,KAWASHIMA H,et al. Malignant transformation of branch duct-type intraductal papillary mucinous neoplasms of the pancreas based on contrast-enhanced endoscopic ultrasonography morphological changes:Focus on malignant transformation of intraductal papillary mucinous neoplasm itself[J]. Pancreas,2012,41(6):855-862. [31] IIBOSHI T,HANADA K,FUKUDA T,et al. Value of cytodiagnosis using endoscopic nasopancreatic drainage for early diagnosis of pancreatic cancer:Establishing a new method for the early detection of pancreatic carcinoma in situ[J]. Pancreas,2012,41(4):523-529. [32] ZHANG H,WU X,ZHU F,et al. Systematic review and meta-analysis of minimally invasive versus open approach for pancreaticoduodenectomy[J]. Surg Endosc,2016,30(12):5173-5184. [33] CAO F,LI J,LI A,et al. Radical antegrade modular pancreatosplenectomy versus standard procedure in the treatment of left-sided pancreatic cancer:A systemic review and metaanalysis[J]. BMC Surg,2017,17(1):67. [34] GAROFALO MC,NICHOLS EM,REGINE WF. Optimal adjuvant therapy for resected pancreatic cancer:Chemotherapy or chemoradiotherapy?[J]. Gastrointest Cancer Res,2007,1(5):182-187. [35] SIDDIQUI AA,MEHENDIRATTA V,LOREN D,et al. Self-expanding metal stents(SEMS)for preoperative biliary decompression in patients with resectable and borderline-resectable pancreatic cancer:Outcomes in 241 patients[J]. Dig Dis Sci,2013,58(6):1744-1750. [36] MEYERS MO,MESZOELY IM,HOFFMAN JP,et al. Is reporting of recurrence data important in pancreatic cancer?[J].Ann Surg Oncol,2004,11(3):304-309. [37] ARNAOUTAKIS GJ,RANGACHARI D,LAHERU DA,et al.Pulmonary resection for isolated pancreatic adenocarcinoma metastasis:An analysis of outcomes and survival[J]. J Gastrointest Surg,2011,15(9):1611-1617. -
本文二维码
计量
- 文章访问数: 4749
- HTML全文浏览量: 62
- PDF下载量: 254
- 被引次数: 0
下载:
